Theravance - THRX | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Theravance - THRX

An SI Board Since October 2004

Posts	SubjectMarks	Bans	Symbol
74	12	0	THRX

Emcee: michael_f_murphy	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
49	Theravance Announces Acceptance of Telavancin MAA for the Treatmentof Complicate	LJM	-	5/30/2007
48	Merrill's take: Theravance Inc (THRX, US$29.22, C-1-9) Beyond Advair Moves	tom pope	-	4/3/2007
47	Theravance Announces Positive Results of Clinical Program in BeyondAdvair Collab	LJM	-	4/2/2007
46	Basilea Announces Positive Top-line Results on Second Pivotal Phase III Ceftobip	dr.praveen	-	1/10/2007
45	>>Theravance to Host Investor Conference Call Following Presentation at th	tuck	-	10/7/2006
44	I don’t know of cases where this happened but it’s a theoretical possibility as	DewDiligence_on_SI	-	8/28/2006
43	<i>In these studies, non-inferiority was needed to claim effectiveness. If	DewDiligence_on_SI	-	8/28/2006
42	Many thanks bio kruncher - that all makes sense now. Peter	Biomaven	-	8/28/2006
41	I think Dew was think of the case where you can find noninferiority and inferior	bio_kruncher	-	8/28/2006
40	<i>hitting on superiority while missing on non-inferiority is rare, but it	Biomaven	-	8/28/2006
39	<i>That wouldn't make any sense to me - that's not a two-bites at	DewDiligence_on_SI	-	8/27/2006
38	<i>They had zero shot at .025 with vanco at 85%.</i> And the sample	Biomaven	-	8/25/2006
37	<i>Two tests: non-inferiority and superiority. Is that the reason it was c	Biomaven	-	8/25/2006
36	They had zero shot at .025 with vanco at 85%. Wonder what their assumptions for	rkrw	-	8/25/2006
35	Two tests: non-inferiority and superiority. Is that the reason it was cut in h	Robohogs	-	8/25/2006
34	<i>The p value needed to show superiority in these trials maybe less than	Biomaven	-	8/25/2006
33	A big selling point for cubicin is it's once daily (same as telavancin), so	rkrw	-	8/23/2006
32	Companies selling against Vanco need to think a little about how this new set of	kenhott	-	8/23/2006
31	Vanco did a lot better in mrsa than I was expecting too, better than the phase I	rkrw	-	8/23/2006
30	I was just thinking off the top of my head that these trials are a combo of both	kenhott	-	8/23/2006
29	Approval is noninferiority as it is for all antibiotic trials. Superiority in mr	rkrw	-	8/23/2006
28	The p value needed to show superiority in these trials maybe less than .05. I j	kenhott	-	8/22/2006
27	My bad - I was just waking up and agree. And if they can get the p stats in the	Robohogs	-	8/22/2006
26	>>I cannot believe that .050 would lead to approval and .053 would not.	IRWIN JAMES FRANKEL	-	8/22/2006
25	Oh so close - I cannot believe that .050 would lead to approval and .053 would n	Robohogs	-	8/22/2006

Go to reply# or date (mm/dd/yy):